Abstract
A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-24 |
| Number of pages | 2 |
| Journal | Investigational New Drugs |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 1992 |
Fingerprint
Keywords
- Didemnin-B
- ovarian cancer
ASJC Scopus subject areas
- Pharmacology
- Molecular Medicine
Cite this
Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study. / Cain, Joanna M.; Liu, P. Y.; Alberts, David S; Gallion, Holly H.; Laufman, Leslie; O'Sullivan, Janet; Weiss, Geoffrey; Bickers, John N.
In: Investigational New Drugs, Vol. 10, No. 1, 03.1992, p. 23-24.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of didemnin-B in advanced epithelial ovarian cancer - A Southwest Oncology Group Study
AU - Cain, Joanna M.
AU - Liu, P. Y.
AU - Alberts, David S
AU - Gallion, Holly H.
AU - Laufman, Leslie
AU - O'Sullivan, Janet
AU - Weiss, Geoffrey
AU - Bickers, John N.
PY - 1992/3
Y1 - 1992/3
N2 - A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
AB - A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.
KW - Didemnin-B
KW - ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=0026683370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026683370&partnerID=8YFLogxK
U2 - 10.1007/BF01275473
DO - 10.1007/BF01275473
M3 - Article
C2 - 1607250
AN - SCOPUS:0026683370
VL - 10
SP - 23
EP - 24
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 1
ER -